PRTC Celea Therapeutics to present Phase 3 IPF trial design
Newsdesk says PRTC Celea Therapeutics will present Phase 3 trial design for idiopathic pulmonary fibrosis and insights from a deupirfenidone drug-drug interaction study at the upcoming ERS Congress.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.